Compare Macy's Inc (M) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Viatris Inc — how do they compare? Macy's Inc trades at $22.63 (market cap $5.95B), while Viatris Inc trades at $17.52 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.4× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Viatris Inc for 57 Days on average.
| M | VTRS | |
|---|---|---|
Market Cap | $5.95B | $20.03B |
Volume | 6,030,644 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $18.27 |
52-Week Low | $16.51 | $9.74 |
Typical Hold Time | 58 Days | 57 Days |
Enterprise Value | $9.75B | $32.15B |
Dividend Yield | 3.36% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $22.79, up 1.47% today, with a bullish technical signal from moving averages. The stock shows attractive valuation with a P/E of 8.35 and P/S of 0.27. Recent earnings have consistently beaten estimates, and the company's 'Bold New Chapter' strategy is driving digital and omnichannel growth, though revenue has trended down from $25.3B in 2022 to $23.0B in 2025.
The outlook is mixed; strong cash flow and a 3.5% dividend yield support income investors, but competitive pressures and uneven growth pose risks. Analyst consensus is a $24.25 price target with a Hold bias. Execution of the turnaround strategy remains key to unlocking value amid retail sector challenges.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
